Chinese CDMO contracted to manufacture Pfizer’s oncology candidate

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/bluebay2014)
(Image: Getty/bluebay2014)

Related tags: CDMO, Pfizer, Cancer, CMAB Biopharma, Kintor Pharmaceuticals

CMAB Biopharma to support Kintor in the clinical development of a potential treatment for liver cancer, ahead of regulatory filing.

Kintor Pharmaceuticals, a Suzhou, China-based R&D company, has reached a collaboration agreement with the Chinese contract development and manufacturing organisation (CDMO) CMAB Biopharma, for the development of activin receptor-like kinase-1 (ALK-1) antibody.

This antibody is a humanized monoclonal antibody (mAb) targeting tumor angiogenesis, initially developed by Pfizer. Kintor was licensed exclusive worldwide rights by Pfizer to develop, manufacture, and commercialize ALK-1 in January 2018, and launched​ Phase II clinical trials for the product in May 2019 in Taiwan.

The drug is currently being tested in combination with nivolumab, in patients with hepatocellular carcinoma (HCC).

Under the agreement, CMAB will provide research and manufacturing services to support clinical development using its cell line development platform. It also will support commercialization and marketing of the product, upon regulatory approvals.

According to CMAB, the companies will work collaboratively in an aim to meet the investigational new drug (IND) application requirements of Chinese and US regulators.

ALK-1 is expressed primarily on vascular endothelial cells and is related to the growth and migration of endothelial cells. By blocking the receptor, ALK-1 can inhibit cancer blood vessel growth, blood flow, and tumor angiogenesis, thus effectively slowing down tumor growth.

During two Phase I clinical trials conducted from 2007 until 2014 by Pfizer in the US, Italy, South Korea, and Japan, the drug demonstrated ‘reasonable’ clinical benefits, according to CMAB, with the potential to be the first fully human therapeutic monoclonal antibody in the world targeting ALK-1.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Related products

show more

Infographic - road map to commercialization

Infographic - road map to commercialization

MilliporeSigma - Gene Therapy | 19-Oct-2020 | Infographic

With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization...

Process Development for Viral Vector Manufacturing

Process Development for Viral Vector Manufacturing

MilliporeSigma - Gene Therapy | 15-Oct-2020 | Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...

Related suppliers

Follow us

Products

View more

Webinars